Neil Issar is an associate in the Litigation Practice Group in the Dallas office of Haynes Boone.
Neil’s practice focuses on healthcare litigation, government investigations, and white collar defense, with particular expertise in fraud and abuse laws (including the False Claims Act, the Anti-Kickback Statute, and the Stark Law), navigation of regulatory and compliance issues involving the healthcare industry, and defending and pursuing antitrust claims. His experience spans both federal and state courts as well as all aspects of complex litigation proceedings, including fact and expert discovery, depositions, motion practice, hearings, trials, and appeals.
In law school, Neil worked as a research assistant and conducted independent studies on the detection and prosecution of healthcare fraud and the admissibility of statistical proof in medical reimbursement coding cases. Before law school, Neil gained experience in medical research, designing and directing various patient-centered clinical trials and health policy studies as well as publishing several papers in peer-reviewed journals.
- Associate, Patrick E. Higginbotham American Inn of Court 2021–2022
- American Bar Association, Section of Health Law
- Dallas Association of Young Lawyers
- Dallas Bar Association
- Health Care Compliance Association
- Included in the "Ones to Watch" category of Best Lawyers in America, Woodward/White, Inc., 2021-2022
- “FDA Guidance in Response to COVID-19 and a Plan for Transition Back to Normal,” co-author, Food and Drug Law Institute’s Update Magazine, Spring 2022.
- “False Claims Act Year in Review,” speaker, Dallas Bar Association Health Law Section, January 19, 2022.
- Ethics Symposium, moderator, Dallas Bar Association Minority Participation Committee, October 21, 2021.
- “Navigating Transition: Practice and Professionalism During Reopening,” speaker, Dallas Bar Association Minority Clerkship Luncheon, June 25, 2021.
- “COVID-19 Legislation Risks & Liabilities for Healthcare Providers,” author, Dallas Bar Association Headnotes, Volume 46, No. 4, April 2021.
- “Mitigating False Claims Act Liability Risks for Healthcare Recipients of COVID-19 Funding,” speaker, Strafford CLE webinar, March 24, 2021.
- “Trends in Telehealth Fraud Enforcement During the COVID-19 Pandemic,” co-author, PLI Chronicle: Insights and Perspectives for the Legal Community, February 2021.
- “False Claims Act Year in Review,” speaker, Dallas Bar Association Health Law Section, January 20, 2021.
- “Government Enforcement Efforts Surrounding the Pandemic,” speaker, Coastal Bend Women Lawyers Association, December 8, 2020.
- White Collar Crimes in Health Law Panel, presenter, Texas A&M University School of Law, October 22, 2020.
- “Update Regarding Courts’ Views on Granston Motions to Dismiss in FCA Cases,” co-author, The Health Lawyer, Volume 33, No. 1, October 2020.
- “Qui Tam Cases: The Impact of the Granston Memo in Practice,” webinar presentation, ABA Health Law Section Fraud & Compliance Interest Group, May 19, 2020.
- “Best Practices for Compliance with the Stark Law and the Anti-Kickback Statute,” webinar presentation, Health Care Compliance Association, February 19, 2020.
- "Recent Developments Provide Guidance to Evaluate FCA Lawsuits," co-author, American Health Lawyers Association (AHLA) Fraud and Abuse Practice Group Bulletin, April 3, 2018.
- “A Balancing Act: Alternative Payment Models and Physician Compensation,” co-author, The Health Lawyer, Volume 30, No. 1, October 2017.
- “Achieving the Promise of Value-Based Purchasing,” co-author, The RAP Sheet, December 2016.
- “More Data Mining for Medical Misrepresentation? Admissibility of Statistical Proof Derived from Predictive Methods of Detecting Medical Reimbursement Fraud,” author, Northern Kentucky Law Review, August 2015.
- “Going Toe-to-Toe with Hydro—Conflicts Between Hydropower and Other Sources of Renewable Power,” author, ABA Renewable, Alternative, and Distributed Energy Resources Committee Newsletter, August 2015.
- “Preemption of State Law Claims Involving Medical Devices: Why Increasing Liability for Manufacturers is a Perilous but Pivotal Proposition,” author, Vanderbilt Journal of Entertainment & Technology Law, July 2015.
- “The Affordable Care Act and Orthopaedic Trauma,” co-author, Journal of Orthopaedic Trauma, October 2014.
- “Do Practice Settings Influence Defensive Medicine in Orthopedic Surgery?”, co-author, American Journal of Orthopedics, August 2014.
- “Health Literacy in an Orthopaedic Trauma Patient Population: Improving Patient Comprehension with Informational Intervention,” co-author, Journal of Orthopaedic Trauma, April 2014.
- “Treating Post-Traumatic Tremor with Deep Brain Stimulation: Report of Five Cases,” co-author, Parkinsonism and Related Disorders, December 2013.
- “Health Literacy in an Orthopaedic Trauma Patient Population: A Cross-Sectional Survey of Patient Comprehension,” co-author, Journal of Orthopaedic Trauma, August 2013.
- “The Link between Texting and Motor Vehicle Collision Frequency in the Orthopaedic Trauma Population,” co-author, Journal of Injury and Violence Research, July 2013.
- “Health Disparities,” co-author, book chapter in An Introduction to Health Policy, June 2013
- “The Role of the CXCR4 Cell Surface Chemokine Receptor in Glioma Biology,” co-author, Journal of Neuro-Oncology, June 2013.
- “Appendiceal Duplication in Children Presenting as an Appendiceal Tumor and as Recurrent Intussusception,” co-author, Journal of Pediatric Surgery, April 2013.
- “Investigational Surgical Therapies,” co-author, book chapter in Handbook of Parkinson’s Disease, Fifth Edition, February 2013.
J.D., Vanderbilt University Law School, 2016, Articles Editor, Vanderbilt Journal of Entertainment & Technology Law
B.S., McGill University, 2010
Judicial Intern to the Honorable Judge Mark Fishburn, Davidson County Criminal Court, 2014
U.S. Court of Appeals for the Fifth Circuit
U.S. Court of Appeals for the Ninth Circuit
U.S. District Court for the Eastern District of Texas
U.S. District Court for the Northern District of Texas
U.S. District Court for the Western District of Texas
From the outset of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) engaged in policymaking at a blistering speed compared to its historically measured pace. Robert Califf, who previously led the agency under Obama, was recently confirmed as FDA commissioner, and Califf’s approach to agency guidance will be closely monitored by many stakeholders. With two COVID-19 [...]